Navigation Links
Childhood Influenza Immunization Coalition Encourages Vaccination Throughout the Influenza Season
Date:11/27/2007

a season may begin as early as October and end as late as May.

New survey data released by the CDC demonstrate that very few people seek influenza vaccination after November. According to a National Health Interview Survey, for the past two influenza seasons approximately 84 percent of all influenza vaccinations were administered during September through November, with a strong peak in early October and a drastic drop by early December. Because many people recommended for vaccination remain unvaccinated at the end of November, the CDC is encouraging public health partners and health care professionals to conduct vaccination clinics and other activities that promote the effectiveness of influenza vaccination during NIVW.

"There is a misconception among parents and others that influenza vaccination can only take place during a narrow period of time each fall. This misconception must be dispelled," said Coalition Moderator, Carol J. Baker, M.D., FAAP, FIDSA, President of NFID and Professor of Pediatrics, Molecular Virology and Microbiology, Baylor College of Medicine. "Because influenza can continue to circulate as late as May, we need to continue providing influenza vaccination to patients who haven't received it throughout the fall and winter."

Denise Palmer of Families Fighting Flu, who lost her 15-month-old daughter to influenza in 2003, and Dan Jernigan, M.D., M.P.H., Deputy Director of the Influenza Division of the National Center for Immunization and Respiratory Diseases at the CDC, are participating in communications activities on Children's Flu Vaccination Day to encourage parents and health care professionals to seek and give influenza vaccinations throughout the fall and winter.

CDC and Families Fighting Flu are member organizations of the Childhood Influenza Immunization Coalition, a coalition made up of 25 of the nation's leading public health, medical, patient and parent groups dedicated to protecting infants, children and adol
'/>"/>

SOURCE Childhood Influenza Immunization Coalition
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
5. Seriously Low Vaccination Rates Cause Experts to Call for Increased Immunization Before Influenza Season Peaks
6. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
7. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
10. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
11. AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 1Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 1Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 7Stroke Damage Is Less in Rats Given Opioids 49194 1